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Patent foramen ovale (PFO) is implicated in platypnea-orthodeoxia, stroke and decompres-
sion sickness (DCS) in divers and astronauts. However, PFO size in relation to clinical illness
is largely unknown since few studies evaluate PFO, either functionally or anatomically. The
autopsy incidence of PFO is approximately 27% and 6% for a large defect (0.6 cm to 1.0 cm).
A PFO is often associated with atrial septal aneurysm and Chiari network, although these
anatomic variations are uncommon. Methodologies for diagnosis and anatomic and func-
tional sizing of a PFO include transthoracic echocardiography (TTE), transesophageal
echocardiography (TEE) and transcranial Doppler (TCD), with saline contrast. Saline
injection via the right femoral vein appears to have a higher diagnostic yield for PFO than via
the right antecubital vein. Saline contrast with TTE using native tissue harmonics or
transmitral pulsed wave Doppler have quantitated PFO functional size, while TEE is
presently the reference standard. The platypnea-orthodeoxia syndrome is associated with a
large resting PFO shunt. Transthoracic echocardiography, TEE and TCD have been used in
an attempt to quantitate PFO in patients with cryptogenic stroke. The larger PFOs
(approximately $4 mm size) or those with significant resting shunts appear to be clinically
significant. Approximately two-thirds of divers with unexplained DCS have a PFO that may
be responsible and may be related to PFO size. Limited data are available on the incidence
of PFO in high altitude aviators with DCS, but there appears to be a relationship. A large
decompression stress is associated with extra vehicular activity (EVA) from spacecraft. After
four cases of serious DCS in EVA simulations, a resting PFO was detected by contrast TTE
in three cases. Patent foramen ovales vary in both anatomical and functional size, and the
clinical impact of a particular PFO in various situations (platypnea-orthodeoxia, thrombo-
embolism, DCS in underwater divers, DCS in high-altitude aviators and astronauts) may be
different. (J Am Coll Cardiol 2001;38:613–23) © 2001 by the American College of
Cardiology
Patent foramen ovale (PFO) has been implicated in several
pathologic processes, including paradoxical embolism in
cryptogenic stroke (1–6) and venous-to-arterial gas embo-
lism (AGE) in serious forms of decompression sickness
(DCS) (an occupational hazard for underwater divers [7–9]
and high altitude aviators and astronauts [10–13]). En-
hanced right-to-left shunting of venous blood through a
PFO in certain pathologic states (14–16), including the
platypnea-orthodeoxia syndrome (17–24), may cause sys-
temic hypoxemia. Only a few studies have attempted to
quantitate the size of a PFO, either functionally or anatom-
ically.
The availability of noninvasive techniques for assessment
of PFO provides the opportunity for clinicians to diagnose
pathologic states that were heretofore difficult to diagnose.
These techniques assess PFO risk based on anatomic and
functional size.
EMBRYOLOGY
Patent foramen ovale is a remnant of the fetal circulation.
Oxygenated placental blood enters the right atrium (RA) via
the inferior vena cava (IVC) and crosses the valve of the
foramen ovale to enter the systemic arterial system (25). The
IVC flow preferentially flows toward the interatrial septum
(IAS) and foramen ovale. The crista interveniens directs
superior vena cava flow away from the IAS. Coronary sinus
flow is also directed away from the IAS (26). At birth,
pulmonary vascular resistance and right-sided cardiac pres-
sures drop with a reversal of the RA-to-left atrium (LA)
pressure gradient. The flap of the foramen ovale (septum
primum) closes against the atrial septum (septum secun-
dum), with fusion usually occurring within the first two
years of life. Fusion is incomplete in about 25% of people,
resulting in an oblique slit-like defect. Termed a PFO, it
functions as a valve-like structure with the “door-jam” on
the LA side of the atrial septum (25) (Fig. 1).
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INCIDENCE
Two autopsy studies determined PFO incidence, with the
first (n 5 1,100) revealing a “probe” patent PFO (0.2 cm to
0.5 cm maximum dimension) in 29% and “pencil” patent
PFO (0.6 cm to 1.0 cm) in 6% (27). The second study (n 5
965) recorded a PFO incidence of 27.3%, with PFOs
varying in size from 1 mm to 19 mm (mean 4.9 mm). The
incidence of PFO declined with age, suggesting that ana-
tomic closure may occur even in adulthood (28).
ASSOCIATED ANATOMICAL STRUCTURES
Atrial septal aneurysm (ASA) (29,30) (Fig. 2) and Chiari
network (31) (Fig. 3) are associated with PFO. Atrial septal
aneurysm incidence is 1% by an autopsy study (32) and 1.9%
by transthoracic echocardiography (TTE) (10,803 subjects)
(33), defining ASA as a septal excursion of $10 mm, with
a base diameter of $15 mm. Another TTE study using an
excursion of $15 mm found an ASA incidence of 0.22%
(34).
A monoplane transesophageal echocardiography (TEE)
study (30) defined ASA excursion $11 mm and base
diameter of 15 mm to compare patients with embolic stroke
(n 5 133) with controls (n 5 277). An ASA was present in
15% of the stroke group and 4% of controls. A PFO was
diagnosed by saline contrast injection in 70% of stroke
patients with an ASA and 75% of controls with an ASA. Of
the 32 ASAs in this study, six had an associated Chiari
network. Notably, TTE identified only 12/32 (37.5%) of
the ASAs. A biplane TEE study (29) found an ASA in
28/355 (7.9%) of stroke patients and 8/363 (2.2%) of
controls. A PFO was found by saline contrast in 56% of
ASA patients. No other possible source of embolism was
found in 24/28 (86%) of the stroke patients with an ASA. In
another study, if a mobile IAS or fossa ovalis measured
$14 mm, there appeared to be an increased PFO incidence
(35). These data indicate that an ASA occurs commonly in
patients with unexplained stroke and is more frequently
detected by TEE than by TTE.
The Chiari network is a remnant of the septum spurium
and the right valve of the sinus venosus resulting from
incomplete resorption of these structures (36). Lace-like
remnants of the original septum may persist and be evident
as coarse or fine fibers in the RA. These fibers originate
from either the Eustachian or Thebesian valve and have
attachments to the upper wall of the RA or IAS. The
Eustachian valve may also be relatively mobile and fenes-
trated but does not attach to the upper wall of the right
atrium or IAS and, therefore, should not be termed a
“Chiari network.”
The autopsy incidence of the Chiari network has been
reported as 2% to 3% (37). A TEE study found a Chiari
network in 29/1,436 (2%), whereas TTE identified only 8.
A TEE-determined PFO was found in 24/29 (83%) of
these, with more “intense” right-to-left shunting noted. An
ASA was found by TEE in 33/1,436 (2.3%), with 7/33
having a coexistent Chiari network (31).
DIAGNOSIS OF A PFO
Before the advent of echocardiography, diagnosis of a
right-to-left shunt was problematic. A PFO without a
significant resting right-to-left shunt is generally not asso-
ciated with any abnormality of the patient history, physical
Abbreviations and Acronyms
AGE 5 arterial gas embolism
ASA 5 atrial septal aneurysm
ASD 5 atrial septal defect
DCS 5 decompression sickness
EMU 5 extravehicular mobility unit
EVA 5 extravehicular activity (spacewalk)
IAS 5 interatrial septum
ISS 5 International Space Station
IVC 5 inferior vena cava
LA 5 left atrium
MRI 5 magnetic resonance imaging
NTH 5 native tissue harmonics
PAVS 5 pulmonary arteriovenous shunt
PFO 5 patent foramen ovale
PV 5 pulmonary vein
RA 5 right atrium
TCD 5 transcranial Doppler
TEE 5 transesophageal echocardiography
TMD 5 transmitral Doppler
TTE 5 transthoracic echocardiography
Figure 1. Longitudinal imaging transesophageal echocardiography in the
midupper esophagus. A large patent foramen ovale (PFO) is evident. The
arrow illustrates how to measure the PFO width. LA 5 left atrium; RA 5
right atrium.
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examination, electrocardiogram or chest radiograph. Heart
catheterization is generally inadequate for diagnosis of PFO,
unless a right heart catheter crosses the IAS into the LA.
On occasion, a transvenous pacemaker wire or pulmonary
artery catheter may inadvertently cross into the LA via an
atrial septal defect (ASD) or PFO. Dye dilution methods
are cumbersome and invasive (38). A relatively noninvasive
method using peripherally injected indocyanine with gen-
eration of a dye dilution curve from a dichromatic earpiece
densitometer was reported in patients with cryptogenic
stroke. A right-to-left shunt was detected in 24/59 (41%);
however, it was not compared with any other diagnostic
modality (39).
Echocardiographic techniques have emerged as the prin-
ciple means for diagnosis and assessment of PFO (Table 1).
In particular, TTE, TEE and transcranial Doppler (TCD)
are commonly used. Peripherally injected agitated saline
may be utilized with TTE to diagnose a right-to-left shunt,
but the yield is rather low compared with TEE. Transcra-
nial Doppler has been used for PFO diagnosis by detection
of air microemboli in a middle cerebral artery after periph-
eral injection of agitated saline. With TTE, the Valsalva
maneuver may enhance color Doppler or agitated saline
contrast detection of a right-to-left shunt, but the acoustic
window may be lost during the maneuver.
Transmitral Doppler (TMD) of mitral flow using periph-
eral injection of agitated saline was compared with TEE
using both contrast and color Doppler for PFO detection
(40). Transesophageal echocardiography detected PFO in
17/44 subjects (39%), with 16 detected by contrast and 1
only by color, the latter having a left-to-right shunt.
Transthoracic echocardiography (TTE) was positive in only
12 of 17 positive TEE-detected PFOs, but all 16 contrast
positive TEEs were positive by TMD. An additional
positive TMD was not detected by TEE. A TMD “bubble
score” and automated quantitative power score correlated
with PFO size measured by TEE.
Transthoracic echocardiography, TTE with native tissue
harmonics (NTH) and TEE were performed with saline
contrast and the Valsalva maneuver in a consecutive group
Figure 2. M-mode (left) and two-dimensional (right) transesophageal echocardiography longitudinal image in the midupper esophagus. The M-mode
demonstrates marked interatrial septum (IAS) mobility, with an excursion .15 mm. By definition this is an atrial septem aneurysm. LA 5 left atrium;
RA 5 right atrium; SVC 5 superior vena cava.
Figure 3. Transesophageal echocardiography in the midupper esophagus at
105°. The arrow points to the mobile Chiari network. IAS 5 interatrial
septum; LA 5 left atrium; RA 5 right atrium; SVC 5 superior vena cava.
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of patients referred to an echocardiography laboratory (n 5
109) for TEE (41). Criteria for PFO detection included
contrast found in the LA within three cardiac cycles after
RA opacification, and “significant” shunts were categorized
as .20 bubbles in the LA. Patent foramen ovale was
identified by TTE in 9/109 subjects (8%), NTH in 21/109
subjects (19%) and TEE in 21/109 subjects (19%). A
“significant” PFO shunt was found in 8 subjects (7%) by
TTE, 17 (16%) by NTH and 12 (11%) by TEE. Two
“significant” shunts detected by NTH were not detected by
TEE. Native tissue harmonics failed to detect four nonsig-
nificant PFOs that were detected by TEE. The advantage of
NTH over TEE was explained by the difficulty patients had
in performing the Valsalva maneuver due to the presence of
an endoscope.
Transesophageal echocardiography is currently consid-
ered the reference standard for PFO diagnosis, allowing
direct imaging of the IAS and saline contrast shunting
through a PFO. If color flow Doppler or peripheral saline
contrast injection detect right-to-left flow during normal
respiration, this is termed a resting PFO. Enhanced right-
to-left flow may be noted upon release of the Valsalva
maneuver.
A methodologic study (n 5 70) in patients with arterial
embolism compared antecubital vein to femoral vein con-
trast injection (Table 2) (42). These data suggest that cough
or the Valsalva maneuver increase the sensitivity of TEE
PFO detection and that contrast injections via the femoral
vein approach are superior to the antecubital route. A
second study comparing the antecubital and femoral vein
approach used TEE and TCD in young patients (n 5 44)
with unexplained neurologic events (Table 3) (43). Al-
though the incidence of PFO by antecubital injection was
much lower than that generally reported by other investi-
gators, contrast injections via the femoral approach had a
higher PFO detection rate.
A false-negative or false-positive TEE for PFO may
occur. A false-negative TEE may result from inadequate
visualization within the esophagus, elevated LA pressures
preventing right-to-left passage of contrast (44,45), IVC-
directed flow along the IAS preventing impingement of
antecubital bubbles against the IAS (42) (Fig. 4) or an
improperly performed Valsalva maneuver.
A TEE false-positive contrast study may occur with a
true ASD (Fig. 5) or a pulmonary arteriovenous shunt
(PAVS). Contrast that has a delayed appearance (.3
cardiac cycles) within the LA after opacification of the RA
may result from a PAVS in which contrast may also be
observed traversing one or more pulmonary veins (PVs).
So-called “debris” entering the LA from PVs may result in
a false-positive TEE (46). Thought to be related to tran-
sient PV stasis, especially during Valsalva maneuver release,
flow was noted to enter the LA. This debris was usually
noted with high gain settings.
PFO SIZE AND CLINICAL SIGNIFICANCE
Autopsy correlation. Patients (n 5 35) were examined for
PFO with both TEE and at subsequent autopsy (47).
Patent foramen ovale size was measured with TEE aided by
color flow Doppler and by quantitating LA contrast using
peripheral venous injections. Nine PFOs found at autopsy
had all been correctly identified ante mortem by color
Doppler TEE. Contrast TEE was negative in one subject
described as having a long interatrial channel. Several
patients with anatomically confirmed PFO had TEE de-
tected left-to-right shunts. All had evidence of high LA
pressures. Color flow Doppler slightly overestimated PFO
size as determined by autopsy. Left atrium contrast was
graded by the maximum number of microbubbles appearing
in a single frame and subsequently compared with autopsy
findings (Table 4).
The platypnea-orthodeoxia syndrome. The platypnea-
orthodeoxia syndrome describes both dyspnea (platypnea)
and arterial desaturation in the upright position with im-
Table 1. Evaluation of Patients for Both Anatomical and
Functional PFO Size
TTE
Anatomy Chiari network
Interatrial septal mobility/atrial septal aneurysm
Diameter of fossa ovalis
Color Doppler Evaluate IVC flow direction
Right-to-left shunt
Left-to-right shunt
Saline contrast (Quantitate bubbles in left heart)
Resting injection
Valsalva injection
TEE
Anatomy Chiari network
Interatrial septal mobility/atrial septal aneurysm
Diameter of fossa ovalis
Evaluate fossa ovalis for ASD
Measure slit between septum primum and
septum secundum
Resting and Valsalva
Color Doppler Evaluate IVC flow direction
Right-to-left shunt
Left-to-right shunt
Measure slit between septum primum and
septum secundum
Resting and Valsalva
Saline contrast (Timing of contrast arrival into LA)
(Quantitate bubbles in LA)
Resting injection
Valsalva injection
TCD Performed in conjunction with TTE and TEE
ASD 5 atrial septal defect; IVC 5 inferior vena cava; LA 5 left atrium; PFO 5
patent foramen ovale; TCD 5 transcranial Doppler; TEE 5 transesophageal
echocardiography; TTE 5 transthoracic echocardiography.
Table 2. TTE PFO Detection by Site of Injection (42)
Spontaneous
Respiration Cough Valsalva Total
Arm 1/70 (1%) 4/70 (6%) 9/70 (13%) 9/70 (13%)
Femoral vein 7/70 (10%) 14/70 (20%) 22/70 (31%) 22/70 (33%)
PFO 5 patent foramen ovale; TTE 5 transthoracic echocardiography.
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provement in the supine position (orthodeoxia) (48,49).
The syndrome occurs with an intracardiac or intrapulmo-
nary shunt and often with some form of lung disease. The
post-pneumonectomy patient (usually the right lung
[18,20]) may develop symptoms many months after the
surgical procedure (17,18,50). A ventilation-perfusion lung
scan, obtained for dyspnea and hypoxia, will reveal systemic
uptake of isotope (21,22,50).
Diagnosis of a PFO with platypnea-orthodeoxia has been
made with a tilt table and saline contrast TTE (17) and
TEE (24). A typical patient history with a significant drop
in oxygen saturation while in the upright position, along
with a large PFO by TEE found as the only source of a
shunt, has been considered diagnostic (22).
Cryptogenic stroke. Efforts to determine anatomical size
and functional significance of a PFO have been expended
most often in patients with embolic stroke (Fig. 6). Patients
(n 5 49) with stroke were evaluated by TTE, TEE and
TCD (51). Transesophageal echocardiography diagnosed
PFO in 19/49 subjects (39%). Transthoracic echocardiog-
raphy was positive in 9/49 subjects (18%) and TCD in
13/49 subjects (27%). No PFOs were detected by TTE and
TCD that were not detected by TEE. All six PFOs not
diagnosed by TCD measured #2 mm by TEE, suggesting
that TCD may only miss small defects.
Another study used TCD and monoplane TEE to
compare 63 controls, 33 patients with stroke that was
explained or “clarified” and 41 patients with cryptogenic
stroke (52). Shunts were sized by quantitating the number
of TCD detected spikes or TEE visualized microbubbles
(Table 5). The TEE score distribution was relatively similar
among the three groups. By TCD, however, the normal
group had a minimal shunt score, and the cryptogenic group
had the largest shunt score, suggesting that TCD may find
predominately clinically significant shunts.
A TEE study with peripheral contrast injection (18 for
source of embolism) detected 34 resting PFOs (53). These
were divided into a small shunt subgroup (n 5 18) with $3
and ,20 LA microbubbles and a large shunt subgroup (n 5
16) with 20. All patients were treated with aspirin or
warfarin and were followed for 21 months. Of the large
shunt subgroup (5/16), 31% had an ischemic event, whereas
there were none in the small shunt subgroup.
Patients ,60 years of age with unexplained neurologic
Table 3. TTE and TCD PFO Detection by Site of Injection (43)
Normal Respiration Valsalva Maneuver
TEE TCD TEE TCD
Arm 5/44 (11.4%) 2/44 (4.5%) 8/44 (18%) 6/44 (13.6%)
Femoral vein 17/44 (38.6%) 16/44 (36%) 22/44 (50%) 22/44 (50%)
PFO 5 patent foramen ovale; TCD 5 transcranial Doppler; TEE 5 transesophageal echocardiography; TTE 5 transthoracic
echocardiography.
Figure 4. Longitudinal transesophageal echocardiography imaging in the midupper esophagus with color Doppler. Blue color is inferior vena cava (IVC)
flow directed along the interatrial septum (IAS). Prominent IVC flow may prevent contrast injected in an upper extremity from opacifying the septum along
the IAS.
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events were compared with normal controls by multiplane
TEE (54) (Table 6). A PFO was diagnosed using peripheral
contrast injection and by direct visualization of the IAS.
Shunt size was measured during normal respiration and
with the Valsalva. Patients with neurologic events had a
significantly higher PFO incidence and size compared with
controls. The large PFO size was found more commonly in
the multiple cerebrovascular accident subgroup. An ASA
was more common in the neurologic event group (12%)
compared with controls (2%), and 19 of the 21 patients with
an ASA had a large PFO (5 6 2 mm). Peripheral saline
contrast shunts were quantitated as minimal (few bubbles in
LA), moderate (“cloud” in LA) or severe (intense opacifi-
cation). Although contrast identified patients with PFO,
there was no significant correlation between measured size
and contrast shunt severity.
Underwater diving and DCS. Decompression sickness
results from the formation of bubbles in body fluids as
Figure 5. Longitudinal transesophageal echocardiography (TEE) imaging in the midupper esophagus. A 32-year-old male presented with an embolic
stroke. He was found to have occult thrombi in both calf veins. Transthoracic echocardiography with peripheral saline contrast during normal respiration
and Valsalva were negative for a right-to-left shunt. (A) TEE revealed a small restrictive secundum atrial septal defect (ASD) (arrow). Note how this
appearance is different from that of a patent foramen ovale. (B) Color Doppler demonstrates a left-to-right shunt with a color mosaic pattern from the shunt
in the right atrium (RA). The ASD was subsequently surgically repaired. LA 5 left atrium; SVC 5 superior vena cava.
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ambient pressure is reduced. Arterial gas embolism is usually
due to air emboli arising from pulmonary barotrauma or
from bubbles in the systemic venous circulation entering the
arterial system. An AGE through an ASD in a scuba diver
was first reported in 1986 (55). Two TTE studies then
demonstrated a relationship between PFO and otherwise
unexplained DCS in divers (7,8). In the first study (n 5 30),
11/30 subjects (37%) had a resting right-to-left shunt (8).
Of the 30 divers, 18 had type II DCS (i.e., serious disease
including neurologic or cardiopulmonary dysfunction as
opposed to type I DCS in which only musculoskeletal pain
is present), and all 11 divers with a resting shunt were in this
group. None of the other 12 divers, who had type I DCS,
had a shunt.
In the second study, antecubital injection was performed
during normal respiration and “modified” Valsalva (7). The
incidence of PFO was 23/53 (43%), but further quantifica-
tion, by counting bubbles in the left ventricle, was not
reproducible from one injection to the next.
A TTE, TEE and TCD study compared commercial
divers (n 5 26) with control subjects (n 5 30) (9). Divers
were categorized as “possible” DCS (transient nonspecific
neurologic symptoms and a normal examination within 48 h
of surfacing), “probable” (significant neurologic dysfunction
but with a normal neurologic examination within 48 h) and
“definite” (significant neurologic dysfunction and an abnor-
mal neurologic examination). A TTE was considered pos-
itive if any bubble appeared in the left heart. By TEE, $3
bubbles in the LA were required for an examination to be
classified as positive, and a study was considered “strongly
positive” if .5 bubbles were seen in a single video frame.
With normal respirations, no difference in PFO detection
rate was noted. By Valsalva maneuver (Table 7), TCD had
the best positive and negative predictive value for detection
of PFO in divers with DCS and was felt to be better than
TEE for delineation of a clinically significant shunt. In
addition, all controls and divers with a strongly positive
TEE had a positive TCD, and all with a positive TCD had
a strongly positive TEE.
Asymptomatic sport divers (n 5 87) were evaluated with
bilateral TCD and a sonicated contrast medium injected
into an antecubital vein (56). A shunt was considered to be
of low relevance if ,20 signals occurred after the Valsalva
maneuver and high relevance if $20 signals were noted.
Magnetic resonance imaging (MRI) brain scans were also
performed (Table 8). All MRI lesions were 2 mm to 3 mm
in size and located in the distribution of the anterior cerebral
circulation. Of note, the three divers with many lesions had
high relevance signals by TCD.
A multiplane TEE study with peripheral agitated con-
trast injection was performed in divers with DCS (n 5 37)
and control divers (n 5 36) (57). Shunts were sized during
Valsalva by quantitating microbubbles in the LA (Table 9).
Of the 37 DCS divers, 20 had type II illness and, of these,
14/20 (70%) had a grade II PFO.
From these studies, it appears that a PFO is associated
Table 4. TTE PFO Size Comparison by Contrast and
Measured Size (47)
Grade (Number of
LA Microbubbles)
Number of
Patients PFO Autopsy Size
I (1–5) 1 #2 mm
2 .2 mm to ,10 mm
II (6–25) 2 .2 mm to ,10 mm
III (.25) 3 $10 mm
LA 5 left atrium; PFO 5 patent foramen ovale; TTE 5 transthoracic echocardio-
graphy.
Figure 6. Longitudinal transesophageal echocardiographic imaging in the midupper esophagus. Arrows point to a thrombus wedged through a patent
foramen ovale and lodged in both the right atrium (RA) and left atrium (LA). SVC 5 superior vena cava.
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with unexplained DCS. A resting PFO and one found by
TCD seem to be associated. Recreational divers without a
clinical history of DCS, but with $20 signals detected by
TCD on a single peripheral injection seemed to have a
higher likelihood of lesions in the anterior cerebral artery
territory, as detected by MRI brain scan.
DCS in high altitude aviators and astronauts. As the
performance of aircraft has evolved over the course of the
last century, both the achieved altitude and rate of climb
have increased. Therefore, hypobaric DCS became a prob-
lem, particularly evidenced during high-altitude bomber
flights in World War II. Several fatal cases occurred in
which the pressure profile and postmortem findings were
documented in some detail (58), with a PFO noted in 5/19
cases. However, no comment was made on the integrity of
the IAS in the reports of several of the remaining autopsies.
Nevertheless, it is clear that a PFO is not invariably present
in all serious cases of altitude DCS.
Altitude exposures occur yearly in hypobaric chambers
utilized by the armed forces of several nations to familiarize
aircrew with the physiologic phenomena associated with
hypoxia and rapid decompression. Altitude DCS is an
uncommon but persistent problem in these exposures; an
overall incidence of about 0.1% is experienced by the U.S.
Armed Forces, with about 10% of these cases manifesting
neurologic or other serious symptoms (59–61).
The contribution of a PFO to these cases of DCS is not
clear, but the prevalence of PFO in U.S. Navy aviators with
serious DCS is reported to be no different from case controls
(10,62). However, these data may not be applicable to all
types of hypobaric pressure profiles. Specifically, the pres-
sure profile used in physiologic training exercises involves a
short exposure (about 15 min) to a modest altitude (about
7,600 m) with subjects at rest. A long hypobaric exposure,
during which heavy work is performed, may be distinct from
these physiologic training profiles and may render a PFO
more important. Presently, the relative risk for altitude DCS
conferred by the presence of a PFO is not well character-
ized.
A large decompression stress is associated with extrave-
hicular activity (EVA) from spacecraft. During the era of
the International Space Station (ISS) construction and
maintenance, two types of “space suits” were utilized, the
Extravehicular Mobility Unit (EMU) developed by the U.S.
and the Russian Orlan suit. To maximize space suit flexi-
bility while maintaining an adequate alveolar oxygen partial
pressure, the suits contain nearly pure oxygen at subatmo-
spheric pressures. The absolute pressure within the EMU is
29.6 kPa, while in the Orlan suit it is 38.6 kPa. Under most
conditions, the cabin atmosphere within all spacecraft uti-
lized in this program (Space Shuttle, proposed “lifeboat”
spacecraft, the Soyuz spacecraft and ISS itself) approximates
sea-level conditions with a composition of 21% oxygen,
balance nitrogen and trace gases, at an absolute pressure of
101 kPa. Consequently, when a crew member transitions
from a spacecraft cabin into a space suit for EVA, there is a
substantial decompression. If this decompression were per-
formed without specific preparation, serious DCS would be
virtually inevitable. To reduce risk of DCS during EVA,
Table 5. Contrast Comparison of TEE and TCD for PFO Shunt Size (52)
TEE
Normal (n 5 63) Clarified CVA (n 5 33) Cryptogenic CVA (n 5 41)
27/63 11/33 27/41
I II III I II III I II III
8/27 15/27 4/27 4/11 5/11 2/11 6/27 8/27 13/27
30% 55% 15% 36% 46% 18% 22% 30% 48%
TCD 28/63 11/33 22/41
I II III I II III I II III
22/28 5/28 1/28 3/11 5/11 3/11 2/22 6/22 14/22
79% 18% 3% 28% 45% 27% 9% 27% 64%
Transesophageal echocardiography microbubbles or TCD spikes were graded as score I: ,10, score II: 10–50 and score III: .50.
CVA 5 cerebrovascular accident; PFO 5 patent foramen ovale; TCD 5 transcranial Doppler; TEE 5 transesophageal
echocardiography.
Table 6. Transesophageal Echocardiography Measured PFO
Size in Otherwise Unexplained TIA, Single CVA and Multiple
CVAs (54)
Control
(n 5 123)
CNS Event (n 5 121)
TIA
(n 5 55)
1 CVA
(n 5 46)
>2 CVAs
(n 5 20)
1PFO 38 (31%) 33 (60%) 37 (80%) 17 (85%)
PFO size (mm) 2 6 1 3 6 1 4 6 2 5 6 2
PFO 1–4 mm 28 (51%) 24 (52%) 4 (20%)
.4 mm 5 (9%) 13 (28%) 13 (65%)
CNS 5 central nervous system; CVA 5 cerebrovascular accident; PFO 5 patent
foramen ovale; TIA 5 transient ischemic attack.
Table 7. TTE, TEE and TCD in Controls and Divers With
DCS (9)
Control
(n 5 30)
Probable/Definite
(n 5 15)
All Divers
(n 5 26)
TTE 5 (17%) 3 (20%) 8 (31%)
TEE 14 (47%) 9 (60%) 15 (58%)
TCD 7 (23%) 7 (47%) 13 (50%)
DCS 5 decompression sickness; TCD 5 transcranial Doppler; TEE 5 transesoph-
ageal echocardiography; TTE 5 transthoracic echocardiography.
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several protocols are utilized that include reductions in cabin
pressure or periods of oxygen breathing before decompres-
sion.
Human terrestrial hypobaric chamber studies indicate
that significant gas phase evolution takes place in body
tissues with all decompression protocols. In particular,
monitoring of the pulmonary artery with Doppler ultra-
sonography reveals that heavy burdens of circulating gaseous
emboli are present in from 6% to 39% of subjects, depend-
ing on the protocol used (63–65) (J. Conkin, personal
communication, 2000). In these studies, serious DCS has
been encountered, including unusual forms such as massive
cutaneous “marbling,” orthostatic instability and severe ce-
rebral dysfunction ([66], J. Conkin, personal communica-
tion, 2000).
A PFO screening was performed after four cases of
serious DCS resulting from EVA-like simulations. A rest-
ing PFO was detected by contrast TTE in three (J.
Waligora, personal communication, 2000).
Conclusions. Patent foramen ovale has been implicated in
platypnea-orthodeoxia, embolic stroke and paradoxical gas
embolism in DCS. Few studies have attempted to quanti-
tate PFO size. Current literature suggests that, when
evaluating a patient for source of embolism, the size of any
detected PFO should be considered since the risk of
trans-septal passage of emboli seems to be greater with
larger lesions.
During TTE and TEE examinations for PFO, one
should evaluate for the presence of an ASA and a Chiari
network because of an association with significant PFOs.
M-mode of the IAS helps facilitate measurement of septal
excursion.
Color flow Doppler by TTE and TEE should be per-
formed to evaluate IVC flow direction into the RA, exam-
ining in particular if IVC flow runs along and, therefore,
potentially across, the IAS. Color flow Doppler should be
used to look for both right-to-left and left-to-right shunting
during normal respiration and after the Valsalva maneuver.
Agitated saline contrast injection should be performed
during normal respiration and the Valsalva maneuver, with
attention to proper timing during the Valsalva maneuver. It
appears that femoral venous injection of contrast, as com-
pared with antecubital injection, increases the incidence of
right-to-left shunt detection, especially during TTE studies.
During a TEE study, observation of agitated contrast
adjacent to the RA-side of the IAS after antecubital contrast
injection may be helpful in that the antecubital injection
probably is accurate.
Individuals who have PFO can be subgrouped according
to many PFO characteristics (large vs. small PFO, provoked
vs. unprovoked trans-septal gas passage, associated anatom-
ical structures). Which methodologic techniques for detec-
tion of those characteristics that are clinically important in
assessing risk of embolic stroke, diver’s DCS and altitude
DCS is not yet entirely clear. The size of PFO probably
matters in determining risk, as does the ease with which
trans-septal passage of emboli occurs in relation to intratho-
racic pressure excursions. Patent foramen ovales are very
common, and not all PFOs are the same. The challenge that
remains is to determine which PFOs and clinical contexts
confer an increased risk of significant disease.
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